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1. Introduction  
Alzheimer’s disease (AD) is an age-related irreversible brain disorder that progresses over 
10 to 20 years. AD gradually destroys human memory and thinking skills, leads to severe 
loss of mental function, and eventually causes death (Querfurth and LaFerla, 2010). 
Normally, AD symptoms first appear after age 65. It is estimated that AD affected 36 million 
people globally in 2009, and the number will be more than doubled by 2050. Currently, 
there is no cure for AD, except few medications that can relieve AD symptoms (Brunden et 
al., 2009; Citron, 2004). 
AD is accompanied by a significant shrunk of brain tissue, which is a result of brain neuron 
degeneration. In the brains of AD patients, neurons are found to have lost their synaptic 
connections with other neurons and are unable to survive (Wenk, 2003). The synaptic failure 
is indeed the earliest event associated with the cognitive impairment caused by the disease 
(Selkoe, 2002). In addition, the brains of AD patients are characterized by the presence of 
two types of hystopathological hallmark lesions: amyloid plaques and neurofibrillary 
tangles (NFTs), which are composed of aggregated proteinaceous material (Tiraboschi et al., 
2004). Although both amyloid plaques and NFTs are also present in brains of healthy 
individuals, the amount of these aggregates in the brains of AD patients is significantly 
higher. Early studies correlated neuron degeneration in AD with the formation of these 
insoluble protein aggregates. However, recent studies suggest that soluble protein 
aggregates of the same protein composition are more toxic to neurons (Rahimi et al., 2008). It 
has also been suggested that the insoluble aggregates actually play a beneficial role in that 
they sequester the toxic soluble aggregates into less toxic or non-toxic insoluble aggregates 
(Greenwald and Riek, 2010).  
At current stage, we are still trying to understand how different protein aggregates in the 
brain mediate neuron degeneration and lead to AD. Like any other protein activity, the 
neurotoxicity of protein aggregates must be associated with their specific molecular 
structures. Therefore, investigating the high-resolution structures of amyloid plaques, NFTs 
and soluble aggregates would greatly facilitate the development of diagnostic and 
therapeutic strategies. Here, in this chapter, we review current knowledge about the 
structure and toxicity of the aggregates involved in AD.  
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2. Structure and toxicity of different protein aggregates involved in AD 
2.1 Amyloid- peptides, tau protein and their relation to AD 
Amyloid plaques are extracellular deposits mainly composed of full length and truncated 
fragments of amyloid- (A) peptides. A peptides are produced upon cleavage of the 
amyloid precursor protein (APP) by - and - secretases (Hooper, 2005). APP is an integral 
membrane protein expressed in many tissues and concentrated in the neuronal synapses 
(Turner et al., 2003). The -secretase protease cleaves APP at different positions, thus 
producing different A fragments composed by 36 to 43 amino-acid-residues (Kang et al., 
1987; Masters et al., 1985). Among those, the A fragments having 40 (A40) or 42 (A42) 
amino-acid-residues are the most common (Hartmann et al., 1997). The amino-acid 
sequences of A40 and A42 are:  
40
42
Aβ :  DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Aβ :  DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA  
In the amyloid plaques, A peptides form highly-ordered insoluble fibrillar aggregates, 
termed amyloid fibrils (Ohnishi and Takano, 2004). Besides, in the brain of AD patients, A 
peptides can also form different types of soluble aggregates, such as small spherical 
aggregates, large spherical aggregates and small curved fibrils that are different from 
mature amyloid fibrils found in amyloid plaques (Dahlgren et al., 2002). An important role 
for of A peptides in AD pathogenesis is also suggested by the fact that many mutations 
related to early-onset familial forms of AD increase total Aβ peptides levels and/or the 
relative concentration of Aβ40 and Aβ42, which is an important factor for AD since the latter 
peptide is more hydrophobic and hince aggregation prone (Borchelt et al., 1996; Eckman et 
al., 1997). 
Neurofibrillary tangles (NFTs) are intracellular deposits mainly composed of the tau 
protein. Normally, tau interacts with tubulins and facilitates their assembly into 
microtubules, which act as cell skeleton and are important for cell health (Hernandez and 
Avila, 2007). Tau sequence can be divided into two major domains: a projection domain and 
a C-terminal microtubules binding domain. The latter contains similar but not identical 
repeats of 31-32 residues responsible for tubulin binding (Kosik, 1990). Six isoforms of tau 
are present in the brain, with 352 to 441 amino-acid-residues (Goedert et al., 1992). They 
differ from each other in the number of tubulin binding domains. Tau can undergo multiple 
types of post-translational modification. Its most important modification in AD is 
phosphorylation. When tau is hyperphosphorylated, it looses binding affinity to the 
microtubules, and starts to self-assemble into paired helical filaments (PHFs), which in turn 
deposit into NFTs (Alonso et al., 2001). Tau deposition as NFTs is also a characteristics of a 
subset of frontotemporal dementia. The fact that mutations in the gene encoding for tau are 
related to familial forms of frontotemporal dementia indicate an important role for tau in 
neurodegeneration (Heutink, 2000). 
In early reports, spreading of NFTs in the brain had been observed to correlate with the 
progression of AD, suggesting a central role for tau in AD, but later studies rather led to the 
dominant idea that the aggregation of A peptides in the brain is the primary event in AD 
and occurs before tau aggregation (Hardy and Selkoe, 2002). The amyloid cascade 
hypothesis for AD proposes that the imbalance between the production and clearance of A 
peptides leads to A aggregation and plaques formation, initiating a complex cascade of 
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events, such as synaptic failure, tau hyperphosphorylation and inflammation, that finally 
lead to AD (Tanzi and Bertram, 2005). So far, the correlation between A amyloid fibrils and 
AD onset remains weak (Schmitz et al., 2004), wheareas soluble A aggregates are believed 
to play the most important role in AD (Rahimi et al., 2008).  
Despite the primary role of A aggregates in AD, A and tau have been demonstrated to 
interact with each other and most likely they cause AD through synergic effects. Indeed, the 
presence of A peptides in transgenic mice influences the aggregation of tau into NFTs and, 
on the other hand, tau protein mediates A toxicity (Lewis et al., 2001; Rapoport et al., 2002). 
Recently, a novel hypothesis linking A and tau has been proposed on the basis of the 
observation that tau can also have a dendritic localization under physiological conditions 
and that tau-mediated postsynaptic targeting of the tyrosine protein kinase FYN confers A 
toxicity (Ittner et al., 2010). 
2.2 Structure of A42 amyloid fibrils 
A42 amyloid fibrils are the most abundant aggregates in amyloid plaques (Roher et al., 
1993). Under electron microscope, they look like unbranched filaments with a diameter of ~ 
10 nm, and their length can reach up to several micrometer (Antzutkin et al., 2002) (Figure 
1A). The X-ray diffraction pattern of aligned A42 amyloid fibrils shows two characteristic 
bands: one sharp band at ~ 4.7 Å position, and another diffused orthogonal band at ~ 10 Å 
(Kirschner et al., 1986) (Figure 1B).  
Two structural models of A42 amyloid fibrils are available. In the first model, the structural 
information was obtained by using solid-state nuclear magnetic resonance (ssNMR) and 
solution NMR combined with the hydrogen/deuterium exchange (H/D-exchange) method. 
The ssNMR techinque provides distance restraints within amyloid fibrils while H/D-
exchange monitored with solution NMR allows the identification of the regions of the 
protein sequence involved in the core structure of amyloid fibrils (Hoshino et al., 2002; 
Wang et al., 2008; Wang et al., 2010). The obtained model shows that: (a) in amyloid fibrils, 
amino-acid-residues 1-10 of A42 are unstructured, residues 11-22 and 31-42 form two -
strands (1 and 2), and residues 23-30 form a bend (Figure 1C) (Ahmed et al., 2010; 
Olofsson et al., 2006); (b) through backbone hydrogen bonds, 1- and 2-strands interact 
with 1- and 2-strands in other A42 molecules and form two parallel -sheets. All -
strands are perpendicular to the fibril axis, and both -sheets are parallel to the fibril axis. 
This structure is called the cross--sheet structure (Figure 1E) (Balbach et al., 2002; Kirschner 
et al., 1986; Tycko, 2004); (c) the two -sheets are connected by the intramolecular side chain 
interaction between Phe19 and Leu34, the salt bridge between Asp23 and Lys28, and the 
intermolecular side chain interaction between Gln15 and Gly37 (Figure 1C & 1F) (Ahmed et 
al., 2010). The distance between two adjacent -strands is ~ 4.7 Å, and the distance between 
two -sheets is ~ 10 Å, corresponding to the two characteristic bands observed in X-ray 
diffraction of amyloid fibrils. 
In the second model, 35MoxA42 was used to produce amyloid fibrils. 35MoxA42 contains a 
methionine sulfoxide at position 35. This structural model was obtained by using solution 
NMR combined with H/D-exchange method and pairwise mutagenesis experiments. The 
resulting structure shows that: (a) in the fibrils, amino-acid-residues 1-17 of 35MoxA42 are 
unstructured, residues 18-26 and 31-42 form two -strands (1 and 2), and residues 27-30 
form a bend (Figure 1D) (Luhrs et al., 2005); (b) 1- and 2-strands in different 
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Fig. 1. Structural model of A42 amyloid fibrils. (A)Electron microscope image of A42 
amyloid fibrils. (B) X-ray diffraction pattern of amyloid fibrils. (C) Illustration of A42 in 
amyloid fibrils. (D) Illustration of MoxA42 in amyloid fibrils. (E) The cross--sheet structure 
of amyloid fibrils. (F) The side chain arrangement in amyloid fibrils. This figure is adapted 
from Fig 4 (Antzutkin et al., 2002), Fig 1 (Ahmed et al., 2010) and Fig 4 (Luhrs et al., 2005).  
35MoxA42 molecules interconnect and form the cross--sheet structure (Figure 1E); (c) the 
two -sheets are connected by the intermolecular side chain interactions between Phe19 and 
Gly38, Ala21 and Val36, and the salt bridge between Asp23 and Lys28 (Figure 1D & 1F) 
(Luhrs et al., 2005). Compared to the structure of A42 amyloid fibrils, the structural 
difference of 35MoxA42 amyloid fibrils may reflect the effect of Met35 modification, or, it may 
reflect the a structural polymorphism of A42 amyloid fibrils. 
2.3 Structure of A40 amyloid fibrils 
A40 can form at least three types of amyloid fibrils with distinct morphology, which include 
striated-ribbon fibrils (Figure 2A), twisted-pair fibrils (Figure 2B) and brain-seeded fibrils 
(Figure 2C) (Paravastu et al., 2009; Petkova et al., 2005). The polymorphism of the fibrils is 
induced by the different conditions used to form them. In particular, incubation of A40 
under agitation leads to the formation of straight-rod shaped protofilaments with a width of 
6 nm, and these protofilaments associate laterally to form striated-ribbon fibrils. Quiescent 
growth rather leads to the formation of twisted-pair fibrils that are composed of single 
protofilaments (Petkova et al., 2005). Seeding A40 aggregation with purified fibrils from 
brain tissue of AD patients leads to the formation of curved and untwisted fibrils (Paravastu 
et al., 2009). All three A40 fibrils have different underlying molecular structures. 
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Fig. 2. Structural model of A40 amyloid fibrils. (A-C) Electron microscope images of 
striated-ribbon fibrils (A), twisted-pair fibrils (B) and brain-seeded (C) amyloid fibrils of 
A40. Scale bar = 100 nm. (D) Illustration of A40 in amyloid fibrils. (E) The parallel cross--
sheet structure of A40 amyloid fibrils. (F) The antiparallel cross--sheet structure of A40–
D23N amyloid fibrils. (G) One protofilament in the striated-ribbon fibrils is composed of 
two cross--sheet units. (H) One protofilament in the twisted-pair fibrils is composed of 
three cross--sheet units. This figure is adapted from Fig 4 (Paravastu et al., 2008), Fig 1 
(Paravastu et al., 2009), and Fig 4 (Sawaya et al., 2007). 
A structural model for striated-ribbon fibrils of A40 was obtained using solid-state NMR 
spectroscopy and electron microscopy. It shows that: (a) in amyloid fibrils, amino-acid-
residues 1-9 of A40 are unstructured, residues 10-22 and 30-40 form two -strands (1 
and 2), and residues 23-29 form a bend (Figure 2D) (Petkova et al., 2006); (b) through 
backbone hydrogen bonds, 1- and 2-strands interact with 1- and 2-strands in other 
A40 molecules and form two parallel -sheets. All -strands are perpendicular to the 
fibril axis, and both -sheets are parallel to the fibril axis. This structure is considered as 
one cross--sheet unit (Figure 2E); (c) the two -sheets are connected by side chain 
interactions, including the intermolecular interaction between Phe19 in one molecule and 
Leu34 in the neighboring molecule, and the intramolecular salt bridge between Asp23 
and Lys28 (Petkova et al., 2006) (Figure 2D); (d) the individual protofilament in the 
striated-ribbon fibrils is composed of two cross--sheet units, which are two-fold 
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rotationally symmetric to each other along the fibril axis (Sciarretta et al., 2005; Tycko, 
2010) (Figure 2G). 
The structural model for twisted-pair fibrils of A40 contains similar cross--sheet unit as in 
striated-ribbon fibrils (Petkova et al., 2006) (Figure 2D & 2E). But the individual 
protofilament in the twisted-pair fibrils is composed of three cross--sheet units, which are 
three-fold rotationally symmetric to each other along the fibril axis (Sciarretta et al., 2005) 
(Figure 2H). This is the biggest difference from the protofilament composed of two cross--
sheet units obtained for striated-ribbon fibrils. Other structural differences in twisted-pair 
fibrils include the absence of the salt bridge between Asp23 and Lys28, and different side 
chain interactions among cross--sheet units. 
Brain-seeded fibrils have been produced to mimic amyloid fibrils of A40 formed in vivo. 
Due to experimental limit, currently it is not possible to measure the structure of fibrils 
directly from human tissue. As an alternative, fibrils extracted from the brain tissue of AD 
patients were used as seeds to produce large amount of isotopically labeled brain-seeded 
fibrils for structural study (Paravastu et al., 2009). These fibrils are thus likely to represent 
the amyloid fibrils formed in vivo. It has been shown that the ssNMR spectra of the brain-
seeded fibrils are different from that of the striated-ribbon or twisted-pair fibrils, suggesting 
that brain-seeded fibrils have a different structure than previous identified structures of 
A40 fibrils (Tycko, 2010). However, a detailed structural model for brain-seeded fibrils is 
not yet available. 
Disease-related mutants of A40 also form amyloid fibrils. The structure of the amyloid 
fibrils formed by the Iowa mutant (A40-D23N), associated with early-onset familial AD, is 
composed of a different cross--sheet unit, in which 1- and 2-strands of A40-D23N 
molecules are interconnected and form two antiparallel -sheets (Tycko et al., 2009) (Figure 
2F). 
2.4 Structure of paired helical filaments of tau 
As mentioned before, neurofibrillary tangles (NFTs) deposits are composed of paired helical 
filaments (PHFs) of tau protein (Wischik et al., 1988) (Figure 3A). Although the high-resolution 
structure of tau PHFs has not been solved yet, several structural models are available based on 
various experimental data. Fourier transform infrared (FT-IR) spectroscopy experiments show 
that tau PHFs are composed of a large amount of random coil structure together with some  
-helical and -sheet structure (Sadqi et al., 2002). It has also been found that the residues 265-
338 in PHFs (PHF43) are protected against proteases digestion, and PHF43 alone can also form 
amyloid fibrils (von Bergen et al., 2000). Further investigation shows that the amino-acid-
residues 306-311 (sequence: VQIVYK) (PHF6) within PHF43 are responsible for PHF43 
amyloid fibrils formation. PHF6 alone forms amyloid fibrils that resemble tau PHFs (von 
Bergen et al., 2005; von Bergen et al., 2000). X-ray microcrystallography data show that PHF6 
forms parallel -sheets in amyloid fibrils, and the -sheets are connected by side chains that 
form steric zippers (Sawaya et al., 2007) (Figure 3B & 3C).  
One structural model of tau PHFs suggests that they contain one cross- sheet composed of 
PHF6 while the rest of the sequence is structurally disordered or contains some -helical 
structure (von Bergen et al., 2005) (Figure 3D). Another structural model suggests that PHFs 
may contain an additional cross- sheet, which is composed of amino-acid-residues 272-289 
(S2) (Figure 3E). This model is based on the finding that isolated S2 can also form amyloid 
fibrils under certain conditions (Margittai and Langen, 2006).  
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Fig. 3. Structural model of paired helical filaments (PHFs) of tau. (A) Electron microscope 
image of tau PHFs. Scale bar = 100 nm. (B-C) The side and top view of the cross--sheet 
structure of PHF6 amyloid fibrils. (D) The proposed structural model for tau PHFs, in which 
PHF6 form the cross--sheet structure, and the rest of tau PHFs is not/least structured. (E) 
Another proposed structural model for tau PHFs, in which PHF6 and S2 form two cross--
sheet structures. This figure is adapted from Fig 1B (Wischik et al., 1988), Fig 2 & 3 (Sawaya 
et al., 2007), Fig 6 (von Bergen et al., 2005) and Fig 4A (Margittai and Langen, 2006).  
2.5 Soluble A aggregates: Mechanism of toxicity and structure 
Increasing evidence suggest that the pathogenic agents in amyloid-related diseases are the 
transient, pre-fibrillar A assemblies preceding the formation of mature fibrils, whereas 
amyloid fibrils rather represent the protective end state of the protein misfolding event 
(Sakono and Zako, 2010; Rahimi et al., 2008; Chiti and Dobson, 2006). This is particularly 
valid in the case of AD, where a weak correlation exists between cognitive impairment and 
amyloid plaques formation (Terry et al., 1991) and, in transgenic mouse lines used to model 
AD, synaptotoxicity is observed before and/or independently of amyloid plaque formation 
(Mucke et al., 2000). Instead, the levels of soluble A oligomers in AD patients correlate 
much better with the onset of neurodegeneration (for a review on the oligomer-toxicity 
hypothesis see Klein et al., 2001). Remarkably, a mutated form of A showing enhanced 
oligomerization but no fibrillation was identified in a Japanese pedigree of AD patients with 
little deposition of fibrillar amyloid (Tomiyama et al., 2008). 
Despite their relevance to disease, a detailed structural and functional characterization of 
amyloid pre-fibrillar species is considerably hampered by their transient and heterogeneous 
nature. In addition, in the case of A pre-fibrillar species, further complications arise due to the 
various methods used to produce the synthetic peptide/s used in the experiments and the fact 
that the A40 and A42 are more aggregation prone than other amyloidogenic peptides and 
protein and form ensembles of oligomeric species already upon dissolution of the lyophilized 
peptides in aqueous buffer (Teplow, 2006). Describing in detail all types of A oligomers 
reported in the literature up to date would be beyond the scopes of this book chapter; we will 
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Fig. 4. Morphology and conformation of different aggregates formed by A42 under 
different incubation conditions. (A) Atomic force microscopy images of ADDLs (left), 
protofibrils (middle) and mature fibrils (right). (B) Schematic model of A42 monomer 
within a spherical pentameric aggregated from solid-state magic angle spinning data. 
Light blue squares connect Phe19 and Leu34. The areas showing little protection from 
hydrogen-deuterium exchange are coloured in green. (C) Model for the structure of A42 
preglobulomers obtained from solution state NMR. According to this model, 
preglobulomers are formed by dimer units adopting mixed parallel and antiparallel 
structure. This figure is adapted from Fig 2 & 4 (Klein et al., 2001), and Fig 3 (Yu et al., 
2009).  
thus limit our description to a summary of the most consolidated and recent information on 
the species thought to play an important role in AD disease. Although all these species are 
generally referred to as “A oligomers”, the readers should keep in mind that they may differ 
in structure, pathway of formation and mechanism of toxicity as well. 
2.5.1 A pre-fibrillar aggregates formed in vitro 
In studies performed in vitro, A peptides have been found to form various types of 
aggregates having spherical morphology. Cross-linking experiments show that A40 and 
A42 preparations differ in their oligomers distributions, with the former peptide forming 
roughly equimolar mixtures of aggregates ranging from dimers to tetramers, whereas the 
latter preferentially forms pentamers/hexamers (termed paranuclei), which self-associate 
into dodecamers and octadecamers (Bitan et al., 2001; Bitan et al., 2003). These larger species 
appear not to be artifacts of the cross-linking technique since A42 stable dodecamers 
formed by stacked hexamer units have been detected also in the absence of any cross-linking 
(Bernstein et al., 2009). Here we will summarize present information on the toxic effect and 
the conformational properties of the most investigated oligomeric species. 
A-derived diffusible ligands (ADDLs) are slowly sedimenting aggregates observed only in 
preparations of synthetic A42 peptides; they appear as globular species with 3-8 nm height 
(Figure 4A) and they are believed to be composed of 3-24 monomers (Oda et al., 1995; 
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Lambert et al., 1998; Klein et al., 2002; Chromy et al., 2003). Their pathological relevance is 
supported by the detection of aggregates (in particular dodecamers) immunoreactive to 
anti-ADDLs antibodies in the brain and cerebrospinal fluid of AD patients (Gong et al., 
2003; Georganopoulou et al., 2005). ADDLs are potent neurotoxins: they induce the death of 
principal neurons of the hippocampus and, in rat hippocampal brain slices, they inhibit 
long-term potentiation (LTP) but not long-term depression (LTD), two forms of synaptic 
plasticity implicated in learning and memory (Lambert et al., 1998; Wang et al., 2002). 
Binding of ADDLs to hippocampal neurons appears to occur at the postsynaptic termini of 
excitatory synapses and stimulates aberrant expression of the activity-regulated 
cytoskeletal-associated (Arc) protein (implicated in long-term memory formation), tau 
hyperphosphorylation, synapses deterioration and loss, and enhanced formation of reactive 
oxygen species (ROS) thought to play a major role in the pathogenesis of AD (Lacor et al., 
2004; Guzowski 2002; Hsieh et al., 2006; De Felice et al., 2007a; De Felice et al., 2007b; Lacor 
et al., 2007; Shankar et al., 2007). Monoclonal antibodies targeting ADDLs can prevent their 
aberrant binding and synaptotoxicity (Lambert et al., 2007). In vivo, insulin signaling and the 
cellular prion protein (PrPC) have been suggested to mediate the toxicity of ADDLs, even if 
in the latter case an effective involvement in AD is currently under debate (De Felice et al., 
2009; Laurén et al., 2009; Gimbel et al., 2010; Calella et al., 2010; Caetano et al., 2011). Despite 
the large amount of data on the toxic effect of ADDLs, still little is known about their 
structure; mainly because they are heterogeneous mixtures of oligomers of different sizes. 
The structure of neurotoxic A42 pentamers has been recently investigated (Figure 4B). 
Hydrogen-deuterium exchange measurements indicate that the first nine residues are 
solvent exposed, as well as residues 13-15, 25-29 and 37-38 that presumably form solvent-
accessible turns (Ahmed et al., 2010). Solid-state magic angle spinning measurements show 
the lack of parallel, in-register -sheets, but the C-terminal regions of the constituting 
monomers are packed together and adopt a conformation similar to that observed in the 
mature fibrils (U-shaped hairpin structure), with Phe19 in contact with Leu34 (Ahmed et al., 
2010). 
Globular oligomers having a size of 4-5 nm, composed of twelve monomeric units and 
forming independently from fibril formation have been obtained from A42 samples 
incubated at high concentration (400 M) in the presence of sodium dodecyl sulfate (SDS) or 
fatty acids; such species are known as A globulomers (Barghorn et al., 2005; Gellermann et 
al., 2008; Yu et al., 2009). Similarly to ADDLs, globulomers selectively bind to neuronal cells, 
inhibit LTP in hippocampal brain slices and their toxicity can be rescued with a globulomer-
specific antibody (Barghorn et al., 2005; Hillen et al., 2010). Moreover, antibodies against 
globulomers detect immunoreactive species in tissue sections from the brains of AD patients 
and human APP transgenic mice (Barghorn et al., 2005). In contrast to ADDLs preparations, 
globulomer samples are stable and homogeneous; thus can be used for structural studies. 
Protease digestion, cross-linking and antibody binding data suggest that residues 1-20 of 
A42 are accessible to the solvent while the rest of the sequence forms the core of the 
aggregates. Solution NMR data on smaller pre-globulomeric species (tetramers) indicate 
that they are composed of dimer repeating units (Figure 4C) with residues 18-23 and 28-40 
forming -structure in mixed parallel and antiparallel -sheets (Yu et al., 2009). Finally, 
hydrogen-deuterium exchange measurements indicate that globulomers and pre-
globulomers have similar secondary structures and that the former species result from 
association of pre-globulomeric units. 
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A40 and A42 can also form, off-pathway from fibril formation, large globular aggregates 
with little or no cross- structure (they do not bind the amyloid-specific dye thioflavin T) 
termed amylospheroids (ASPDs) (Hoschi et al., 2003; Matsumura et al., 2011). ASPDs of 10-
15 nm diameter are potent neurotoxins to primary cultures from rat septum regions; the 
most toxic species being 32-mers (Hoschi et al., 2003; Matsumura et al., 2011). Antibodies 
generated to recognize ASPDs stain AD brains and have been used to immunoisolate 
ASPDs directly from AD and dementia with Lewy bodies brains (Noguchi et al., 2009). 
Levels of ASPDs in AD patients correlate with the severity of disease and the 
immunoprecipitated species induce degeneration on neurons in vitro (Noguchi et al., 2009). 
Chimon et al. investigated the structure of globular A40 aggregates formed by at least 150 
monomers that impair the viability of cultured PC-12 cells and have a diameter similar to 
that of ASPDs, but, in contrast to ASPDs, they are rich in -sheet structure and are on-
pathway intermediates of fibril formation (Chimon and Ishii, 2005; Chimon et al., 2007). 
Solid-state NMR spectra show that these assemblies have ordered parallel, in regisister, -
stucture, extremely similar to that of mature A40 fibrils, particularly in the hydrophobic 
core and C-terminal regions (Chimon and Ishii, 2005; Chimon et al., 2007). 
A protofibrils (Figure 4A) also belong to the wide range of possible A pre-fibrillar 
aggregates. These are soluble aggregates formed by both A40 and A42 via association of 
smaller globular units, with an apparent mass higher than 100 kDa and appearing as curved 
fibril-like structures of 3-8 nm diameter and less than 200 nm length (Harper et al., 1997; 
Walsh et al., 1997; Walsh et al., 1999; Harper et al., 1999). PFs formed in vitro alter the 
viability of cultured rat primary cortical neurons and induce neuronal injury, impaired 
electrophysiological activities and neuronal loss (Walsh et al., 1999; Hartley et al., 1999). The 
fact that the early-onset AD-related Arctic mutation enhances PF formation suggests that 
these species might be relevant for the disease (Nilsberth et al., 2001). Moreover, 4-hydroxy-
2-nonenal (HNE), a metabolite of oxidative stress found to exist at increased concentrations 
in AD patients and to co-localize with A deposits, causes in vitro accumulation of A40 PFs 
and prevents their conversion into mature fibrils, thus leading to sustained neurotoxicity to 
cultured cells (Sayre et al., 1997; Siegel et al., 2007; Johansson et al., 2007). PFs appear 
transiently and are considered to be the direct precursors of long and rigid amyloid fibrils 
(Harper et al., 1997; Walsh et al., 1997). Indeed, they already possess a high content of -
sheet structure and the capability to bind the WO1 amyloid fibrils-specific antibody 
(Williams et al., 2005). Nonetheless, they are still metastable and can dissociate into low 
molecular weight oligomers (Walsh et al., 1999; Harper et al., 1999). A40 PFs possess a 
stable structural core (Kheterpal et al., 2003). Proline substitution and hydrogen-deuterium 
exchange experiments on A40 PFs stabilized by a small molecule show that the first N-
terminal 14-19 residues and the C-terminal 3-5 residues are not involved in the formation of 
their structural core and that, in comparison to mature fibrils, PFs are less structured in the 
fragment spanning residues 20-34 (Williams et al., 2005; Kheterpal et al., 2006). 
Protofibrillar aggregates formed by the E22G (Arctic mutation) mutant of A40 can also 
adopt annular structures (Lashuel et al., 2002). These species have a pore-like appearance 
with an outer diameter of 7-10 nm and an inner diameter of 1.5-2.0 nm, and appear to be 
composed of 40-60 peptide molecules (Lashuel et al., 2002). Structures similar to annular PFs 
have been observed upon incorporation of different A peptides into artificial and natural 
membranes and have been hypothesized to serve as calcium channels that mediate A-
induced toxicity in AD (Arispe et al., 2007). However, the formation of A pores is still 
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debated since spherical A aggregates can increase membrane permeability and 
intracellular calcium levels without any evidence of discrete channel of pore formation 
(Kayed et al., 2004; Demuro et al., 2005). Antibodies specific for annular protofibrils, but not 
spherical oligomers and fibrils, also recognize heptameric alpha-hemolysin pores, 
suggesting that the antibody recognizes an epitope that is specific for a  barrel structural 
motif (Kayed et al., 2009). 
2.5.2 Cell-derived pre-fibrillar aggregates 
Oligomerization studies performed in vitro with synthetic peptides have various limitations: 1) 
the usually employed peptide concentrations are in the micromolar range, whereas A 
concentration in vivo is rather in the nanomolar or even subnanomolar range (Seubert et al., 
1992; Suzuki et al., 1994; Tabaton et al., 1994); 2) in vitro, peptides of specified lengths are used, 
whereas numerous A species, with extensive amino and carboxyl terminal heterogeneity, are 
usually present in vivo (reviewed in Golde and Younkin, 1996); 3) aggregation is usually 
examined under non-physiological conditions, with the peptides solubilized in organic 
solvents and then diluted in water or aqueous buffers free of other proteins, macromolecules 
or small molecules. These limitations imply that pathologically relevant aggregates may differ 
substantially from those produced in vitro. Thus, considerable effort has been recently spent in 
isolating and characterizing A oligomers formed in vivo. Detailed structural characterization 
of cell-derived oligomers is lacking due to their low concentration, but their ability to cause 
toxicity and cognitive impairment has been deeply investigated. 
Small SDS-stable oligomers have been isolated at nanomolar concentration from the 
medium of caltured cells, human cerebrospinal fluid, APP transgenic mouse brain and 
human brain (reviewed in Selkoe 2008; Rahimi et al., 2008). A dimers have been detected 
and proved to form intracellularly in primary human neurons and in both neuronal and 
non-neural cell lines (Walsh et al., 2000). Stable dimers and trimers of A isolated from the 
neuritic plaques of AD patients and leptomeningeal vessels compromise the viability of 
cultured rat hippocampal neuron glia cells through a microglia-dependent mechanism and 
A dimers from the cerebral cortex of AD patients can also impair synaptic plasticity and 
memory in rats (Roher et al., 1996; Shankar et al., 2008). Synaptic dysfunction is also caused 
by dimers from ex vivo human cerebrospinal fluid (Klyubin et al., 2008). 
Oligomers (in particular trimers) secreted in the medium of Chinese Hamster Ovary cells 
over-expressing the -amyloid precursor protein inhibit hippocampal LTP, decrease the 
density of dendritic spines, impair cognitive function in rats and inhibit the remodeling of 
synapses, a prerequisite for memory consolidation (Walsh et al., 2002; Cleary et al., 2005; 
Townsend et al., 2006; Shankar et al., 2007; Poling et al., 2008; Freir et al., 2010). Compounds 
that inhibit oligomers formation or antibodies that bind to the oligomers rescue their toxic 
effects (Walsh et al., 2005a; Walsh et al., 2005b).  
A soluble, SDS-stable dodecamer termed A*56 was found in the brain of middle-aged APP 
transgenic mice carrying a familial AD-linked double mutation (Lesné et al., 2006). Levels of 
A*56 dodecamers in middle-aged APP transgenic mice correlate with cognitive deficits and 
administration of purified A*56 to young rats disrupts their memory (Lesné et al., 2006). In 
a recent study, synthetic A42-derived oligomers, cell- and brain-derived low molecular 
weight oligomers, and A*56 have been compared for their ability to produce deficits in 
learned behavior of rats, finding that dimers derived from the culture medium of APP 
transgenic cells are the most potent neurotoxins (Reed et al., 2009). 
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Oligomers of modified forms of N-terminally truncated A peptides having pyroglutamate 
as first residue in the sequence (pE-A) have also been detected in the cerebral cortex of AD 
patients (Piccini et al., 2005). pE-A peptides are believed to play an important role in the 
pathogenesis of AD because they are highly abundant in the brains of AD patients and they 
are major constituents of the amyloid plaques (for a recent review, see Gunn et al., 2010). In 
vitro studies indicate that pE-A peptides are more aggregation prone and neurotoxic than 
full length A (Harigaya et al., 2000; Russo et al., 2002). When a novel mouse monoclonal 
antibody specifically targeting low molecular weights oligomers of pE-A is used to 
passively immunize transgenic mice, plaque load and A levels are reduced and behavioral 
deficits are normalized, suggesting that pE-A oligomers are valuable targets for AD 
diagnosis and therapeutic intervention (Wirths et al., 2010). 
3. Conclusion 
In this chapter, we reviewed current knowledge of the structure and toxicity of different 
protein aggregates that are involved in Alzheimer’s disease (AD). Currently, two structural 
models are available for A42 amyloid fibrils. Both models show a parallel cross--sheet 
structure. But in the first model, amino-acid-residues 11-22 and 31-42 adopt -strand 
conformation (A42); wheareas in the second model, residues 18-26 and 31-42 adopt -strand 
conformation (35MoxA42). For A40 amyloid fibrils, structural polymorphism has been 
observed. The striated-ribbon fibrils, twisted-pair fibrils and brain-seeded fibrils of A40 all 
have different morphology and molecular structure. Tau PHFs also contain a cross--sheet 
structure, in which amino-acid-residues 306-311 and possibly 272-289 adopt the -strand 
conformation. The rest of tau is either disordered or contains small amount of -helical 
structure.  
Recent studies suggest that the soluble A aggregates (pre-fibrillar aggregates), instead of A 
amyloid fibrils and tau PHFs, correlate more closelly with neuron degeneration in AD. Several 
types of A pre-fibrillar aggregates have been described. Their common toxicity may be due to 
multiple reasons such as the heterogeneity of A aggregates preparations, most likely 
containing different amounts of monomeric, oligomeric and fibrillar A rather than single 
species, and the fact that all these species may share a “misfolded” nature, meaning that they 
most likely expose on their surfaces repetitive clusters and/or arrays of groups that enable 
their interaction with different targets. It has been recently suggested that it’s the ongoing A 
polymerization process involving the elongation and growth of pre-fibrillar aggregates such as 
protofibrils, rather than the formation of a specific toxic oligomeric species to be responsible 
for A toxicity in AD (Jan et al., 2011). Similarly to what has been proposed for another 
amyloid forming peptide, the cooperative binding of A peptides to cell membranes, and the 
growth and elongation of A aggregates at the level of the membrane could result in changes 
in membrane curvature and weakened lipid packing, leading to membrane permeabilization 
and toxicity (Engel et al., 2008; Friedman et al., 2009). Further studies are therefore necessary to 
clearly elucidate the structural properties and mechanism of toxicity of A aggregates in order 
to develop efficient therapeutic strategies for AD. 
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